

7 May 2019
ASX Code: MXC

Arrival of first CannEpi™ shipment to United Kingdom

A
S
X

R
E
L
E
A
S
E

- First shipment of CannEpi™ landed in the UK for distribution to medical doctors
- Confirms immediate acceptance and increasing interest from pharmacists and prescribing doctors in the United Kingdom (UK) for cannabis derived medicines like CannEpi™
- Official access now in the UK where the market size for cannabis medicinal uses expected to reach €8.8bn¹ by 2028
- Reinforces MGC Pharma’s strategy of Europe being a major focus in the distribution of its cannabis derived products

MGC Pharmaceuticals Ltd (ASX: MXC, “MGC Pharma” or “the Company”) a leading international integrated cannabinoid bio-pharma company, is pleased to announce the first shipments of CannEpi™, its proprietary formulation used to relieve symptoms such as seizures associated with severe epilepsy cases, has arrived in the UK for immediate distribution to pharmacies, or direct to medical patients. This represents a ground breaking point in the distribution of CannEpi™ and the growing acceptance of cannabis derived products being prescribed by doctors in the UK to treat drug resistant conditions.

CannEpi™ is an oral oil solution used to relieve symptoms such as seizures associated with severe epilepsy cases, where conventional medicines and therapies have failed to control them (Drug Resistant Epilepsy). It was developed by MGC Pharma’s specialist Research and Development division which both grew the relevant cannabis strains and formulated the solution on the back of extensive and long-term observational studies.

The changes in UK regulations on 1 November 2018, which legalised the use of medicinal cannabis, has allowed specialist doctors to prescribe medical cannabis to their patients. Market Access specialists, Grow Biotech PLC and IPS Specials already received initial prescriptions in the UK for CannEpi™ highlighting the increasing interest from doctors and pharmacies looking to use medical cannabis for the relief from symptoms of drug resistant conditions. The estimated value of the medicinal cannabis market in the UK in 2028 post legalisation is €8.8bn¹. The legalisation in the UK of the medicinal use of cannabis derived products adds to a growing number of European jurisdictions where their uses are now legal, catching up with regulation changes already seen in North America.

¹ Source: [Prohibition Partners: The European Cannabis Report™ 4th Edition](#)
info@mgcpharma.com.au | mgcpharma.com.au
MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth, WA 6005
PO Box 1976, West Perth WA 6872
T: +61 8 6382 3390

As recently announced, CannEpi™ is being distributed by Grow Biotech PLC, a British headquartered company developing revolutionary processes, practices, techniques, tools and formulations to bridge the gap between existing cannabis medicines and accepted pharmaceutical standards, and IPS Specials, a company that manufactures unlicensed compounded medications and formulations for community and hospital pharmacists, and dispensing doctors.

Grow Biotech and IPS provide direct, official access into the UK medical cannabis market with an extensive network of some 5,500 pharmacies across the UK.

The Company has developed a number of other products including CogniCann™ specifically formulated for the relief of key Dementia and Alzheimer’s symptoms and improving specific cognitive functions, InCann™ for the relief from symptoms of Chron’s Disease and IBS, and TopiCann™, a topical treatment to reduce psoriasis and eczema appearance.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:

“The first CannEpi™ shipment landing in the UK represents a true milestone in the history of MGC Pharma and the relief from symptoms of epilepsy. The legalisation of medicinal cannabis passed in the UK only 7 months ago, and the subsequent increasing interest in CannEpi™ leading to orders from medical professionals, is testament to the importance of our products into the fast-growing UK market, and beyond. Over half a million people in the UK suffer from epilepsy², and CannEpi™ has the potential to significantly enhance the lives of sufferers. We look forward to keeping shareholders updated as we see increased market penetration of our products.”

--Ends--

For further information, please contact:

Media Enquiries

Justin Kelly
Media and Capital Partners
+61 408 215 858
Justin.kelly@mcpartners.com.au

UK IR/Media Advisors

Gaby Jenner/ Catherine Leftley
St Brides Partners Ltd
+44 (0) 207 236 1177
gaby@stbridespartners.co.uk
catherine@stbridespartners.co.uk

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 6382 3390
info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU-based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   

² Source: [Epilepsy Society](#)